Background

Washington is reviewing new regulatory approaches to address China’s rapid biotech growth. Recently, policymakers and industry leaders have been urging an expansion of the COINS Act’s scope. This suggests that a regulation previously limited to the financial sector may be extended to the biotech arena.

Rationale for the Policy

The increase in overseas biotech drug licensing agreements by Chinese companies is perceived to raise the risk of technology leakage in the United States. Consequently, the Treasury Department aims to tighten foreign direct investment restrictions to protect national security. This move could safeguard the competitiveness of U.S. biotech firms while also influencing international trade norms.

Impact on the Industry

If the regulation is broadened, U.S. biotech companies are likely to require additional approvals when entering contracts with Chinese partners. This would increase transaction costs and cause project delays, thereby elevating risk for investors. Conversely, domestic firms may encounter a shifting competitive landscape that creates new market opportunities.

Future Scenarios

Should the regulatory application be confirmed, short‑term interactions with China may contract, while long‑term U.S. biotech innovation could be stimulated. Because the policy remains unsettled, markets should remain vigilant to uncertainty, and companies should explore alternative partnerships and diversify supply chains.